Drug details:
Molecular formula: C₂₈H₂₄Cl₂N₂O₅

Standard name: (5E)-5-[[4-[(2,4-dichlorophenyl)methoxy]-3-ethoxyphenyl]methylidene]-1-(3,5-dimethylphenyl)-1,3-diazinane-2,4,6-trione

Synonym:

(5E)-5-{4-[(2,4-dichlorobenzyl)oxy]-3-ethoxybenzylidene}-1-(3,5-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione

Curated SMILES: CCOC1=C(C=CC(=C1)/C=C/2\C(=O)NC(=O)N(C2=O)C3=CC(=CC(=C3)C)C)OCC4=C(C=C(C=C4)Cl)Cl

Evidence for compound's anti-virulence activity:

Clostridium
Related VF: theta-toxin/PFO (Perfringolysin O)
Target: PfoA
Drug effect: Blocks Perfringolysin O (PFO)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PFO-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.

Streptococcus
Related VF: Pneumolysin
Target: Ply
Drug effect: Blocks Pneumolysin (PLY)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PLY-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.